NAD+ Injections: Human Evidence, Safety, and Expectations
VA Health & Wellness2 min read
In short
NAD+ is a coenzyme, not a peptide. Injectable NAD+ is promoted for energy and healthy aging, but the reviewed human studies do not establish broad fatigue relief or age reversal. Research on infusion metabolism or tolerability should not be treated as proof of benefit from every NAD+ preparation or route.
On this page
Key takeaways
- Why is NAD+ discussed for energy?
Its role in cellular metabolism makes the molecule biologically important.
- What have human studies measured?
A 2019 pilot examined plasma and urine metabolite changes during intravenous NAD administration.
- What safety concern has FDA highlighted?
FDA has warned about ingredients unsuitable for sterile compounding and reported severe chills, shaking, vomiting, and fatigue after NAD+ injections, with some people requiring medical treatment.
- What should be said about compounding status?
FDA's May 2026 503A nominated-substances list includes nicotinamide adenine dinucleotide in Category 1.
- How can you compare expectations with evidence?
Ask which outcome the proposed plan is meant to improve and which study actually tested it.
- Put fatigue and wellness goals in context
Our B12 article and product-category guide explain other common catalog questions.
Why is NAD+ discussed for energy?
Its role in cellular metabolism makes the molecule biologically important. That does not automatically mean administering more improves a person's symptoms. If you feel fatigued, tell the clinician how long it has lasted and what has changed. Ask whether the concern needs further evaluation before selecting a wellness product. A cellular explanation should not replace a symptom-focused assessment.
What have human studies measured?
A 2019 pilot examined plasma and urine metabolite changes during intravenous NAD administration. [S23] (opens in a new tab) A 2026 retrospective study compared NAD+ and nicotinamide riboside infusions, focusing on tolerability and short-term markers. [S24] (opens in a new tab) Neither design establishes a general claim of longer life or better daily energy from home injections. The route, endpoints, limited follow-up, and commercial context matter when interpreting the results.
What safety concern has FDA highlighted?
FDA has warned about ingredients unsuitable for sterile compounding and reported severe chills, shaking, vomiting, and fatigue after NAD+ injections, with some people requiring medical treatment. The alert discusses possible endotoxin-related reactions. [S25] (opens in a new tab) This should not be described as a precise rate of harm, because adverse-event reports do not supply that information. It does show why quality and symptom assessment matter.
What should be said about compounding status?
FDA's May 2026 503A nominated-substances list includes nicotinamide adenine dinucleotide in Category 1. [S07] (opens in a new tab) That conditional interim-policy listing is not approval of a finished NAD+ medicine or proof of clinical benefit. The ingredient form, route, pharmacy framework, and current requirements need verification. Do not assume a 503A listing settles the rules for a 503B facility.
How can you compare expectations with evidence?
Ask which outcome the proposed plan is meant to improve and which study actually tested it. Distinguish evidence about NAD+, oral precursors, and related substances. Discuss preparation quality, practical burden, cost, alternatives, and the plan if symptoms occur. Avoid accepting “cellular energy” as a sufficient outcome measure. The goal should be clear enough to determine whether further treatment discussion is warranted.
Put fatigue and wellness goals in context
Our B12 article and product-category guide explain other common catalog questions. VA Health & Wellness's care overview can help prepare your visit. This article provides education and does not endorse NAD+ for fatigue disorders, cognitive enhancement, disease prevention, or anti-aging.
Frequently asked questions
Sources
[S23] Grant et al., Frontiers in Aging Neuroscience: Pilot study of plasma and urine NAD metabolome during IV infusion (opens in a new tab)
[S24] Reyna et al., Frontiers in Aging: IV NAD+ versus nicotinamide riboside: retrospective tolerability pilot (opens in a new tab)
Related reading
Peptide Medicines, Supplements, NAD+, and B12: What Is Different?
October 14, 2026 · 2 min read
B12 Injections and Fatigue: Deficiency Versus Energy Claims
Peptide Therapy Safety: Side Effects and Questions to Ask
October 12, 2026 · 2 min read